<DOC>
	<DOCNO>NCT02409134</DOCNO>
	<brief_summary>Psychological well-being cognitive function measure patient enrol primary study , NCT01790568 , phase 2 trial vorinostat plus tacrolimus methotrexate prevent graft versus host disease follow unrelated donor hematopoietic stem cell transplantation . Validated questionnaire administer assess patient ' level depression , anxiety , quality life , perceive cognitive functioning , sleep quality . Cognitive test include reliable valid measure process speed , attention , executive function , episodic memory , visual learn memory . The purpose study determine whether measure feasible administer patient early time point bone marrow transplantation .</brief_summary>
	<brief_title>Cognitive Function Patient-Reported Quality Life Outcomes Investigation Patients Taking Vorinostat</brief_title>
	<detailed_description />
	<mesh_term>Graft v Host Disease</mesh_term>
	<mesh_term>Vorinostat</mesh_term>
	<criteria>Patients must enrol parent study ( NCT01790568 ; A phase 2 clinical trial vorinostat plus tacrolimus methotrexate prevent graft versus host disease follow unrelated donor hematopoietic stem cell transplantation ) Must speak , read understand English Documented evidence cognitive impairment prior enrollment study ( diagnosis dementia , mild cognitive impairment , neurological illness impact cognition ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Bone Marrow Transplantation</keyword>
	<keyword>Hematologic Malignancies</keyword>
	<keyword>Adults</keyword>
	<keyword>Cognition</keyword>
</DOC>